ACADIA Pharmaceuticals Inc. Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending March 30, 2021 was -21.56% (a -74.27% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth increased by 380.18%
  • Annual Research and Development (R&D) Expenses Growth for 2020 was 10.79% (a -62.06% decrease from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2019 was 28.44% (a 11.75% increase from previous year)
  • Annual Research and Development (R&D) Expenses Growth for 2018 was 25.45% (a -49.36% decrease from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending March 30, 2021 was -23.93% (a 114.23% increase compared to previous quarter)
  • Twelve month trailing Research and Development (R&D) Expenses Growth decreased by -249.19% year-over-year
Trailing Research and Development (R&D) Expenses Growth for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
-23.93% -11.17% 13.28% 16.04%
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of ACADIA Pharmaceuticals Inc.

Most recent Research and Development (R&D) Expenses Growthof ACAD including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -21.56%
2020 -83.8% 7.44% -4.49% 37.25% 10.79%
2019 19.38% 17.91% 44.49% 34.75% 28.44%
2018 11.59% 45.83% 36.31% 10.92% 25.45%
2017 42.89% 41.1% 66.91% 55.47% 50.26%
2016 47.65% 37.82% 11.42% 39.77% 34.41%
2015 12.56% 10.48% 33.19% 39.66% 21.89%
2014 129.41% 133.69% 94.02% 163.39% 126.79%
2013 61.72% 64.86% 59.03% -11.77% 42.18%
2012 10.78% 5.82% 3.64% 13.8% 8.58%
2011 -7.02% -16.25% -14.4% -24.13% -15.89%
2010 -39.29% -46.12% -57.92% -50.51%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.